{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:10:23Z","timestamp":1760127023535,"version":"build-2065373602"},"reference-count":74,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Evidera"},{"name":"Pfizer Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>A combined Haemophilus influenzae type b (Hib)\/meningococcal serogroup C (MenC) vaccine will soon be unavailable in the UK immunisation schedule due to discontinuation by the manufacturer. An interim statement by the Joint Committee on Vaccination and Immunisation (JCVI) advises stopping MenC immunisation at 12 months of age when this occurs. We undertook an analysis of the public health impact of various potential meningococcal vaccination strategies in the UK in the absence of the Hib\/MenC vaccine. A static population-cohort model was developed evaluating the burden of IMD (using 2005\u20132015 epidemiological data) and related health outcomes (e.g., cases, cases with long-term sequelae, deaths), which allows for the comparison of any two meningococcal immunisation strategies. We compared potential strategies that included different combinations of infant and\/or toddler MenACWY immunisations with the anticipated future situation in which a 12-month MenC vaccine is not used, but the MenACWY vaccine is routinely given in adolescents. The most effective strategy is combining MenACWY immunisation at 2, 4, and 12 months of age with the incumbent adolescent MenACWY immunisation programme, resulting in the prevention of an additional 269 IMD cases and 13 fatalities over the modelling period; of these cases, 87 would be associated with long-term sequelae. Among the different vaccination strategies, it was observed that those with multiple doses and earlier doses provided the greatest protection. Our study provides evidence suggesting that the removal of the MenC toddler immunisation from the UK schedule would potentially increase the risk of unnecessary IMD cases and have a detrimental public health impact if not replaced by an alternate infant and\/or toddler programme. This analysis supports that infant and toddler MenACWY immunisation can provide maximal protection while complementing both infant\/toddler MenB and adolescent MenACWY immunisation programmes in the UK.<\/jats:p>","DOI":"10.3390\/vaccines11050940","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T03:57:31Z","timestamp":1683259051000},"page":"940","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?"],"prefix":"10.3390","volume":"11","author":[{"given":"Katharina","family":"Schley","sequence":"first","affiliation":[{"name":"Pfizer Pharma GmbH, Linkstra\u00dfe 10, 10785 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack C.","family":"Kowalik","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Dorking Rd., Tadworth KT20 7NS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Evidera\/PPD, 27-35, rue Victor Hugo, 94853 Ivry-sur-Seine CEDEX, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Vyse","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Dorking Rd., Tadworth KT20 7NS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Czudek","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Dorking Rd., Tadworth KT20 7NS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Tichy","sequence":"additional","affiliation":[{"name":"Evidera\/PPD, Bocskai ut 134-144, Dorottya Udvar, Building E, Floor 2, H-1113 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Pfizer Ltd., Walton Oaks, Dorking Rd., Tadworth KT20 7NS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Purmohamad, A., Abasi, E., Azimi, T., Hosseini, S., Safari, H., Nasiri, M.J., and Imani Fooladi, A.A. (2019). Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. Microb. Pathog., 134.","DOI":"10.1016\/j.micpath.2019.103571"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Voss, S.S., Nielsen, J., and Valentiner-Branth, P. (2022). Risk of sequelae after invasive meningococcal disease. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07129-4"},{"key":"ref_4","unstructured":"Public Health England (2023, April 18). Invasive Meningococcal Disease in England: Annual Laboratory Confirmed Reports for Epidemiological Year 2019 to 2020. Health Protection Report. Volume 15, Number 1, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/951142\/hpr0121_imd-ann.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","article-title":"Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015","volume":"36","author":"Parikh","year":"2018","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","article-title":"Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: A national surveillance and modelling study","volume":"6","author":"Campbell","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_7","unstructured":"Public Health England (2023, April 18). MenC Vaccine Schedule and Planned Changes from July 2016, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/512311\/2016_MenC_infant_schedule_letter-FINAL__1_.pdf."},{"key":"ref_8","unstructured":"Public Health England (2023, April 18). Invasive Meningococcal Disease in England: Annual Laboratory Confirmed Reports for Epidemiological Year 2020 to 2021. Health Protection Report. Volume 16, Number 2, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1049331\/hpr0122-IMD-ann__1_.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","article-title":"Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease","volume":"24","author":"Beck","year":"2021","journal-title":"Value Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1649.e1","DOI":"10.1016\/j.cmi.2022.07.004","article-title":"Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: Evidence for herd protection from the UK MenACWY programme","volume":"28","author":"Carr","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.28206","article-title":"Meningococcal serogroup Y emergence in Europe: High importance in some European regions in 2012","volume":"10","author":"Broker","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Knol, M.J., Ruijs, W.L., Antonise-Kamp, L., de Melker, H.E., and van der Ende, A. (2018). Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Eurosurveillance, 23.","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158"},{"key":"ref_14","unstructured":"Gov.Uk (2023, April 18). Chapter 22, Meningococcal, Immunisation against Infectious Disease the Green Book, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1076053\/Meningococcal-greenbook-chapter-22_17May2022.pdf."},{"key":"ref_15","unstructured":"Joint Committee on Vaccination and Immunisation (2023, April 18). Meeting Minutes, June 2022. Available online: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/993200326824."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14760584.2021.1878030","article-title":"Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada","volume":"20","author":"Huang","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","unstructured":"Meningitis Research Foundation (MRF) (2023, April 18). MenC and Hib Meningitis: Responding to JCVI Recommended Changes. Available online: https:\/\/www.meningitis.org\/welcome-to-our-newsroom\/menc-and-hib-meningitis-responding-to-jcvi-recommended-changes."},{"key":"ref_18","unstructured":"Joint Committee on Vaccination and Immunisation (2023, April 18). Meeting Minutes, June 2021. Available online: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/849032554320."},{"key":"ref_19","unstructured":"Joint Committee on Vaccination and Immunisation (2023, April 18). Meeting Minutes, February 2020. Available online: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/636396626894."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: Considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","article-title":"Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community","volume":"34","author":"Ultsch","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cid\/ciab791","article-title":"Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study","volume":"74","author":"Ohm","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Borja-Tabora, C.F.C., Peyrani, P., Webber, C., Van der Wielen, M., Cheuvart, B., De Schrevel, N., Bianco, V., Aris, E., Cutler, M., and Li, P. (2020). A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05104-5"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","article-title":"Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1\u201310 Years of Age","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hec.3259","article-title":"Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis","volume":"25","author":"Brouwer","year":"2016","journal-title":"Health Econ."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Guedes, S., Bricout, H., Langevin, E., Tong, S., and Bertrand-Gerentes, I. (2022). Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017\u2014A secondary database analysis. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-12933-3"},{"key":"ref_28","unstructured":"National Institute for Health and Care Excellence (2023, April 18). NICE Health Technology Evaluations: The Manual. Process and Methods [PMG36]. Available online: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation."},{"key":"ref_29","unstructured":"Office for National Statistics, Northern Ireland Statistics and Research Agency, and National Records of Scotland and Welsh Government (2023, April 18). Population Data, 2020, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland."},{"key":"ref_30","unstructured":"World Health Organization (WHO) (2023, April 18). Defeating Meningitis by 2030: A Global Road Map. Licence: CC BY-NC-SA 3.0 IGO. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240026407."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","volume":"34","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: A cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jinf.2019.12.008","article-title":"Invasive meningococcal disease: Timing and cause of death in England, 2008\u20132015","volume":"80","author":"Beebeejaun","year":"2020","journal-title":"J. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1080\/21645515.2021.1996808","article-title":"Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile","volume":"17","author":"Cavada","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England","volume":"38","author":"Beck","year":"2020","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.3201\/eid2709.204866","article-title":"Invasive Meningococcal Disease, 2011-2020, and Impact of the COVID-19 Pandemic, England","volume":"27","author":"Subbarao","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Taha, M.K., and Deghmane, A.E. (2020). Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05241-9"},{"key":"ref_39","unstructured":"England, P.H. (2023, April 18). Meningococcal ACWY Immunisation Programme: Vaccine Coverage Estimates, Available online: https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20220120225806\/https:\/\/www.gov.uk\/government\/publications\/meningococcal-acwy-immunisation-programme-vaccine-coverage-estimates."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.vaccine.2020.12.080","article-title":"Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020","volume":"39","author":"Middeldorp","year":"2021","journal-title":"Vaccine"},{"key":"ref_41","unstructured":"Adams, L., Trotter, C., Hadley, L., Campbell, H., and Ramsay, M. (2022, January 18\u201319). Estimating the potential number of cases prevented by infant\/toddler immunisation with a MenACWY Vaccine. Proceedings of the United Kingdom Health Security Agency Conference 2022, Leeds, UK."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","article-title":"Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Clark, S., Campbell, H., Mensah, A.A., Lekshmi, A., Walker, A., Ribeiro, S., Walsh, L., Willerton, L., Bai, X., and Lucidarme, J. (2021). An Increase in Group B Invasive Meningococcal Disease Among Adolescents and Young Adults in England Following Easing of COVID-19 Containment Measures. SSRN, 1\u201311.","DOI":"10.2139\/ssrn.3998164"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(06)70466-2","article-title":"Interactions between influenza and bacterial respiratory pathogens: Implications for pandemic preparedness","volume":"6","author":"Brundage","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3201\/eid2808.220304","article-title":"Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England","volume":"28","author":"Bertran","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dagan, R., Danino, D., and Weinberger, D.M. (2022). The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic. JAMA Netw. Open, 5.","DOI":"10.1001\/jamanetworkopen.2022.18966"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Choi, Y.H., and Miller, E. (2021). Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: A mathematical modelling study. BMJ Open, 11.","DOI":"10.1136\/bmjopen-2020-045380"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1093\/cid\/ciab1014","article-title":"Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study","volume":"75","author":"Danino","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Willen, L., Ekinci, E., Cuypers, L., Theeten, H., and Desmet, S. (2021). Infant Pneumococcal Carriage in Belgium Not Affected by COVID-19 Containment Measures. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.825427"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Taine, M., Offredo, L., Drouin, J., Toubiana, J., Weill, A., Zureik, M., and Dray-Spira, R. (2021). Mandatory Infant Vaccinations in France During the COVID-19 Pandemic in 2020. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.666848"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1661","DOI":"10.1093\/cid\/ciaa1244","article-title":"First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England","volume":"73","author":"Ladhani","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","article-title":"Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease","volume":"11","author":"Scholz","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: Targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jval.2022.01.025","article-title":"The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies","volume":"25","author":"Ma","year":"2022","journal-title":"Value Health"},{"key":"ref_55","unstructured":"Public Health England (2023, April 18). Quarterly Vaccination Coverage Statistics for Children Aged up to Five Years in the UK (COVER Programme): October to December 2019. Health Protection Report. Volume 14, Number 7 2020 updated 27 March 2020, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/875855\/hpr0720_AA_COVER.pdf."},{"key":"ref_56","unstructured":"European Center for Disease Prevention and Control (ECDC) (2023, April 18). Surveillance Atlas of Infectious Diseases. Invasive meningococcal disease\u2014Confirmed UK cases by age-group for serogroups ABCWY. 2005 to 2015. Available online: https:\/\/www.ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): A case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s10096-012-1610-1","article-title":"Arthritis related to systemic meningococcal disease: 34 years\u2019 experience","volume":"31","author":"Cabellos","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/INF.0000000000001048","article-title":"The Burden of Pediatric Invasive Meningococcal Disease in Spain (2008\u20132013)","volume":"35","author":"Salvado","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s11136-004-7706-z","article-title":"Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis","volume":"14","author":"Koomen","year":"2005","journal-title":"Qual. Life Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jinf.2010.07.006","article-title":"Cognitive functioning and quality of life nine years after bacterial meningitis","volume":"61","author":"Schmand","year":"2010","journal-title":"J. Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","article-title":"Long-term Effects of Child Death on Parents\u2019 Health Related Quality of Life: A Dyadic Analysis","volume":"59","author":"Song","year":"2010","journal-title":"Fam. Relat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK","volume":"26","author":"Gani","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1192\/bjp.bp.106.025106","article-title":"Impact of psychiatric disorders on health-related quality of life: General population survey","volume":"190","author":"Saarni","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2105\/AJPH.2011.300173","article-title":"Arthritis, occupational class, and the aging US workforce","volume":"101","author":"Lee","year":"2011","journal-title":"Am. J. Public Health."},{"key":"ref_68","first-page":"393","article-title":"Measuring burden of disease: Disability-Adjusted Life Years (DALY)","volume":"Volume II","author":"Burazeri","year":"2013","journal-title":"Health Investigation: Analysis-Planning-Evaluation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","article-title":"The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: A head-to-head comparison","volume":"55","author":"Oostenbrink","year":"2002","journal-title":"J Clin Epidemiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11136-010-9783-5","article-title":"EuroQol (EQ-5D) health utility scores for patients with migraine","volume":"20","author":"Xu","year":"2011","journal-title":"Qual. Life Res."},{"key":"ref_71","unstructured":"Stouthard, M.E.A., Essink-Bot, M.L., Bonsel, G.J., Barendregt, J.J.M., Kramers, P.G.N., van de Water, H.P.A., Gunning-Schepers, L.J., and van der Maas, P.J. (1997). Disability Weights for Diseases in the Netherlands, Department of Public Health, Erasmus University. Available online: https:\/\/pure.uva.nl\/ws\/files\/3238153\/3276_ddw.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wyld, M., Morton, R.L., Hayen, A., Howard, K., and Webster, A.C. (2012). A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med., 9.","DOI":"10.1371\/journal.pmed.1001307"},{"key":"ref_73","first-page":"114","article-title":"Quality of life and QALYs in the measurement of health","volume":"18","author":"Yfantopoulos","year":"2001","journal-title":"Arch. Hell. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population","volume":"85","author":"Brown","year":"2001","journal-title":"Br. J. Ophthalmol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/940\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:29:07Z","timestamp":1760124547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["vaccines11050940"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11050940","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2023,5,4]]}}}